76987B28-B56B-4A1F-B77C-1E08B8EFEF90
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 30.650459921156372
- age_years
- 45
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.502
- WNT_BETA_CATENIN_SIGNALING+0.418
- INTERFERON_GAMMA_RESPONSE+0.373
- CHOLESTEROL_HOMEOSTASIS+0.355
- MTORC1_SIGNALING+0.308
- UNFOLDED_PROTEIN_RESPONSE+0.306
- MYC_TARGETS_V1+0.301
- HEDGEHOG_SIGNALING+0.300
- MYC_TARGETS_V2+0.293
- DNA_REPAIR+0.271
Top 10 suppressed
- ANGIOGENESIS-0.305
- KRAS_SIGNALING_DN-0.258
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.237
- COAGULATION-0.234
- MYOGENESIS-0.220
- APICAL_SURFACE-0.125
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.119
- APICAL_JUNCTION-0.118
- SPERMATOGENESIS-0.092
- BILE_ACID_METABOLISM-0.072
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E16AD7E1-29DA-4B8F-8B12-A8A6BBAA9174 | — | — | 0.875 |
| 2 | C81B24AB-2DBA-4624-A1D4-D4DCAC714506 | — | — | 0.872 |
| 3 | 37DF227E-8B22-4757-A65C-87C6F28F87D4 | — | — | 0.871 |
| 4 | SRR934819 | — | — | 0.863 |
| 5 | 7E7AAFFD-6EEB-4357-88AD-9EB12BB78602 | — | — | 0.844 |
| 6 | 46AD8592-A823-48DA-AB51-3CEC34F53E04 | — | — | 0.833 |
| 7 | D837BDD1-8786-4548-8D5F-8506AECF2006 | — | — | 0.833 |
| 8 | C6ACBA34-164B-419D-9C2B-ED2DC3C68FDD | — | — | 0.830 |
| 9 | 7E9D6B6D-3276-4240-B5C5-F3F982076358 | — | — | 0.830 |
| 10 | SRR934756 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.502 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.418 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.373 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.355 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.308 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.306 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.301 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.293 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.271 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.269 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.238 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.232 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.222 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.221 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.207 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.202 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.195 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |